Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

The invention provides a method for the extraction of an organic acid (10) from a mixture (110), the method comprising: an extraction stage comprising providing the mixture (110) to a sorbent (150); an elution stage comprising passing an eluent along the sorbent (120) to provide an eluate (140), wherein the eluent (130) comprises a solvent selected from the group consisting of acetone and alcohols, and wherein the eluent (130) comprises at least 0.1 M of OH, and wherein the eluent (130) comprises at least 0.1 M of an cation selected from the group comprising Na.sup.+, K.sup.+, Ca.sup.2+, Mg.sup.2+ and NH.sup.4+; a precipitation stage comprising providing CO.sub.2 (150) to the eluate (140), wherein the CO.sub.2 (150) and the cation form a carbonate, wherein the carbonate precipitates; and a separation stage comprising separating the organic acid (10) from the eluate (140).

The invention provides a method for the extraction of an organic acid (10) from a mixture (110), the method comprising: an extraction stage comprising providing the mixture (110) to a sorbent (150); an elution stage comprising passing an eluent along the sorbent (120) to provide an eluate (140), wherein the eluent (130) comprises a solvent selected from the group consisting of acetone and alcohols, and wherein the eluent (130) comprises at least 0.1 M of OH, and wherein the eluent (130) comprises at least 0.1 M of an cation selected from the group comprising Na.sup.+, K.sup.+, Ca.sup.2+, Mg.sup.2+ and NH.sup.4+; a precipitation stage comprising providing CO.sub.2 (150) to the eluate (140), wherein the CO.sub.2 (150) and the cation form a carbonate, wherein the carbonate precipitates; and a separation stage comprising separating the organic acid (10) from the eluate (140).

The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.

The present invention relates to a process for the preparation of aqueous solutions of [1-.sup.13C]-hyperpolarized carboxylate containing molecules of diagnostic interest that comprises parahydrogenating with molecular para-hydrogen unsaturated alkenyl or alkynyl esters of the concerned .sup.13C-carboxylate molecules.

The present invention relates to a process for the preparation of aqueous solutions of [1-.sup.13C]-hyperpolarized carboxylate containing molecules of diagnostic interest that comprises parahydrogenating with molecular para-hydrogen unsaturated alkenyl or alkynyl esters of the concerned .sup.13C-carboxylate molecules.

The present invention relates to a process for the preparation of aqueous solutions of [1-.sup.13C]-hyperpolarized carboxylate containing molecules of diagnostic interest that comprises parahydrogenating with molecular parahydrogen unsaturated alkenyl or alkynyl esters of the concerned .sup.13C-carboxylate molecules.

The present invention relates to a process for the preparation of aqueous solutions of [1-.sup.13C]-hyperpolarized carboxylate containing molecules of diagnostic interest that comprises parahydrogenating with molecular parahydrogen unsaturated alkenyl or alkynyl esters of the concerned .sup.13C-carboxylate molecules.

The present disclosure relates to psilocin compounds and pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, to pharmaceutical compositions, and in some embodiments, to serotonin 5-HT.sub.2 receptor agonists and uses in the treatment of diseases associated with a 5-HT.sub.2 receptor.

##STR00001##

The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to multiple-component phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.